Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and tri-fab (TFM)

British Journal of Cancer

Volumn 74, Issue 4, 1996, Pages 513-524

  Antoniw, P ^a   Farnsworth, Aph ^a   Turner, A ^a   Haines, Amr ^a   Mountain, A ^a   Mackintosh, J ^a   Shochat, D ^b   Humm, J ^c   Welt, S ^c   Old, L J ^c   Yarranton, G T ^d   King, D J ^a  

^a UCB PHARMA   (Belgium)

^b PFIZER INC   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d NONE

Author keywords

Antibody; Radioimmunotherapy; Tri Fab; Yttrium

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IODINE 125; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTORADIOGRAPHY; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG CLEARANCE; DRUG PENETRATION; DRUG TOXICITY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LIVER METASTASIS; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR LOCALIZATION; XENOGRAFT;

EID: 9444227576     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.395     Document Type: Article

References (48)

1. ADAM T. (1989). Radioiodination for therapy. Ann. Clin. Biochem., 26, 244 - 245.
2. 131I-labelled antibodies. Antibody Immumoconj. Radiopharm., 3, 281 - 287.
3. 131I-monoclonal antibody A33 (abstract 2844). Proc. Am. Assoc. Cancer Res., 34, 477.
4. BEHR TM, SHARKEY RM, JUWEID M, ANINPOT R, GRIFFITHS GL AND GOLDENBERG DM. (1995). Reduction of kidney uptake of radiolabelled monoclonal antibody (MAb) fragments: preclinical and initial clinical results. J. Nucl. Med., 36, 19P - 20P.
5. 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model. Int. J. Cancer, 4, 292 - 300.
6. BOXER GM, ABASSI AM, PEDLEY RB AND BEGENT RHJ. (1994). Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA) - implications for targeted therapy. Br. J. Cancer, 69, 307 - 314.
7. 2 fragments. J. Clin. Invest., 83, 1449 - 1456.
8. 2 fragments are more effective and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J. Nucl. Med., 31, 1035 - 1044.
9. BUCHSBAUM DJ. (1995). Experimental radioimmunotherapy and methods to increase therapeutic efficacy. In Cancer Therapy with Radiolabelled Antibodies, Goldenberg DM (ed.) pp. 115 - 140, CRC Press: Boca Raton, USA.
10. BURAS RR, WONG JYC, KUHN JA, BEATTY BG, WILLIAMS LE, WANEK PM AND BEATTY JD. (1993). Comparison of radioimmunotherapy and external beam radiotherapy in colon cancer xenografts. Int. J. Radiat. Oncol. Biol. Phys., 25, 473 - 479.
11. CHEUNG NKV, LANDMEIER B, NEELY J, NELSON AD, ABRAMOWSKY C, ELLERY S, ADAMS RB AND MIRALDI F. (1986). Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J. Natl Cancer Inst., 77, 739 - 745.
12. COLCHER D, HORAN-HAND P, NUTI M AND SCHLOM J. (1981). A spectrum of monoclonal antibodies reactive with human mammary tumour cells. Proc. Natl Acad. Sci. USA, 78, 3199-3203.
13. COLCHER D, MILENIC D, ROSELLI M, RAUBITSHEK A, YARRANTON GT, KING D, ADAIR J, WHITTLE N, BODMER M AND SCHLOM J. (1989). Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res., 49, 1738 - 1745.
14. COX JP, JANKOWSKI KJ, KATAKY R, PARKER D, BEELEY NRA, BOYCE BA, EATON MAW, MILLAR K, MILLICAN AT, HARRISON A AND WALKER C. (1989). Synthesis of a kinetically stable yttrium-90 labelled macrocycle-antibody conjugate. J. Chem. Soc. Chem. Commun., 1989, 797-798.
15. DENARDO GL, KROGER LA, DENARDO SJ, MIERS LA, SALAKO Q, KUKIS DL, FAND I, SHEN S, RENN O AND MEARES CF. (1994). Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer Suppl., 73, 1012 - 1022.
16. ESTEBAN JM, SCHLOM J, MORTNEX F AND COLCHER D. (1987). Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumours and normal organs. Eur. J. Cancer Clin. Oncol., 23, 643 - 655.
17. GOLDENBERG DM, GAFFAR SA, BENNETT SJ AND BEACH JL. (1981). Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res., 41, 4354 - 4360.
18. 90Y from cyclic and acyclic ligand-antibody conjugates. Nucl. Med. Biol., 18, 469-476.
19. HARWOOD PJ, BRITTON DW, SOUTHALL PJ, BOXER GM, RAWLINGS G AND ROGERS GT. (1986). Mapping epitope characteristics on carcinoembryonic antigen. Br. J. Cancer, 54, 75 - 82.
20. HYAMS DM, ESTEBAN JM, BEATTY BG, WANEK PM AND BEATTY JD. (1989). Prolongation of survival of nude mice bearing human colon cancer. Arch. Surg., 124, 175-179.
21. JAIN RJ. (1989). Delivery of novel therapeutic agents in tumours: physiological barriers and strategies. J. Natl Cancer Inst., 81, 570-576.
22. 212Bi) therapy. Cancer Res., 53, 5683-5689.
23. KING DJ, TURNER A, FARNSWORTH APH, ADAIR JR, OWENS RJ, PEDLEY RB, BALDOCK D, PROUDFOOT KA, LAWSON ADG, BEELEY NRA, MILLAR K, MILLICAN TA, BOYCE B, ANTONIW P, MOUNTAIN A, BEGENT RHJ, SHOCHAT D AND YARRANTON GT. (1994). Improved tumour targeting with chemically cross-linked recombinant antibody fragments. Cancer Res., 54, 6176-6185.
24. KING DJ, ANTONIW P, OWENS RJ, ADAIR JR, HAINES AMR, FARNSWORTH APH, FINNEY H, LAWSON ADG, LYONS A, BAKER TS, BALDOCK D, MACKINTOSH J, GOFTON C, YARRANTON GT, MCWILLIAMS W, SHOCHAT D, LEICHNER P, WELT S, OLD LJ AND MOUNTAIN A. (1995). Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br. J. Cancer, 72, 1364-1372.
25. KNOX SJ. (1995). Overview of studies on experimental radioimmunotherapy. Cancer Res. (suppl.), 55, 5832s-5836s.
26. 2 antibodies. Br. J. Cancer, 70, 521-525.
27. 121I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J. Clin. Invest., 72, 2101-2114.
28. 90Y-labelled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques. Cancer Res., 50, 4546-4551.
29. LOEVINGER R, BUDINGER TF AND WATSON EE. (1991). MIRD Primer for Absorbed Dose Calculations. The Society of Nuclear Medicine Inc: New York.
30. LYONS A, KING DJ, OWENS RJ, YARRANTON GT, MILLICAN A, WHITTLE NR AND ADAIR JR. (1990). Site specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Engin., 3, 703-708.
31. MAACK T, JOHNSON V, KAU ST, FIGUEIREDO JA AND SIGULEM D. (1979). Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int., 16, 251 - 270.
32. MACH JP, PELEGRIN A AND BUCHEGGER F. (1991). Imaging and therapy with monoclonal antibodies in non-hematopoietic tumours. Curr. Opin. Immunol., 3, 685-693.
33. MOI MK, DENARDO SJ AND MEARES CF. (1990). Stable bifunctional chelates of metals used in radioimmunotherapy. Cancer Res. (suppl.), 50, 789s-793s.
34. 131I anti-CEA antibody in a colonic xenograft model. Br. J. Cancer, 68, 69 - 73.
35. PRESS OW, EARY JF, APPELBAUM FR, MARTIN PJ, BADGER CC, NELP WB, GERNN S, BUTCHKO G, FISHER D, PORTER B, MATTHEWS DC, FISHER LD AND BERNSTEIN ID. (1993). Radiolabelled antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Eng. J. Med., 329, 1219-1224.
36. RICHMAN PI AND BODMER WF. (1988). Control of differentiation in human colorectal carcinoma cell lines: epithelial mesenchymal interactions. J. Pathol., 156, 197 - 211.
37. SCHOTT ME, FRAZIER KA, POLLOCK DK AND VERBANAC KM. (1993). Preparation, characterization and in vivo biodistribution properties of synthetically cross-linked multivalent antitumour antibody fragments. Bioconjugate Chem., 4, 153-165.
38. SCHOTT ME, SCHLOM J, SILER K, MILENIC DE, EGGENSPERGER D, COLCHER D, CHENG R, KRUPER WJ, FORDYCE W AND GOECKLER W. (1994). Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labelled immunoconjugates. Cancer Suppl., 73, 993-998.
39. SENEKOWITSCH R, REIDEL G, MOLLENSTADT, KRIEGEL H AND PABST HW. (1989). Curative radioimmunotherapy of human mammary carcinoma xenografts with iodine-131-labeled monoclonal antibodies. J. Nucl. Med., 30, 531 - 537.
40. SHARKEY RM, MOTTA-HENNESSY C, PAWLYK D, SIEGAL JA AND GOLDENBERG DM. (1990). Biodistribution and radiation dose estimates for yttrium and iodine labelled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res., 50, 2330 - 2336.
41. SIEGAL JA, WESSELS BW, WATSON EE, STABIN MG, VREISENDORP HM, BRADLEY EW, BADGER CC, BRILL AB, KWOK CS, STICKNEY DR, ECKERMAN KF, FISHER DR, BUCHSBAUM DJ AND ORDER SE. (1990). Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj. Radiopharm., 3, 213-233.
42. STEPHENS S, EMTAGE S, VETTERLEIN O, CHAPLIN L, BEBBINGTON C, NESBITT A, SOPWITH M, ATHWAL D, NOVAK C AND BODMER M. (1995). Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology, 85, 668-674.
43. 90Y-labelled monoclonal antibody CO17-1A, a potential agent for radioimmunotherapy of colorectal carcinoma. Nucl. Med. Biol., 15, 707 - 711.
44. 90Y-labelled monoclonal antibody CO17-1A. Antibody Immunoconj. Radiopharm., 4, 729 - 734.
45. WELT S, DIVGI CR, REAL FX, YEH SD, PILAR GC, FINSTAD CL, SAKAMOTO J, COHEN A, SIGURDSON ER, KEMENY N, CARSWELL EA, OETTGEN HF AND OLD LJ. (1990). Quantitative analysis of antibody localization in human metastatic colon cancer: studies with monoclonal antibody A33. J. Clin. Oncol., 8, 1894 - 1896.
46. WELT S, DIVGI CR, KEMENY N, FINN RD, SCOTT AM, GRAHAM M, GERMAIN JS, CARSWELL-RICHARDSE, LARSON SM, OETTGEN HF AND OLD LJ. (1994). Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol., 12, 1561 - 1571.
47. YOKOTA T, MILENIC DE, WHITLOW M AND SCHLOM J. (1992). Rapid tumor penetration of a single chain Fv and comparison with other immunoglobulin forms. Cancer Res., 52, 3402 - 3408.
48. YORKE ED, BEAUMIER PL, WESSELS BW, FRITZBERG AR AND MORGAN JR AC. (1991). Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics. Nucl. Med. Biol., 18, 827-835.